Efficacy and Safety of Subcutaneous Spesolimab for the Prevention of Generalised Pustular Psoriasis Flares (Effisayil 2): an International, Multicentre, Randomised, Placebo-Controlled Trial

home / between-the-lines / efficacy-and-safety-of-subcutaneous-spesolimab-for-the-prevention-of-generalised-pustular

Bruce Strober, MD, PhD, introduces an upcoming series highlighting a clinical trial focused on the efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares.

Revolutionizing GPP Management: The Efficacy and Safety of Spesolimab in Preventing Life-Threatening Flares

EP. 1: Revolutionizing GPP Management: The Efficacy and Safety of Spesolimab in Preventing Life-Threatening Flares

October 29th 2024

Explore the groundbreaking findings from the Effisayil 2 trial on the efficacy and safety of subcutaneous spesolimab in preventing flares of generalized pustular psoriasis.

Study Objectives and Key Inclusion Criteria for GPP Patients

EP. 2: Study Objectives and Key Inclusion Criteria for GPP Patients

October 29th 2024

Delve into the complexities of generalized pustular psoriasis (GPP), a rare and life-threatening skin condition, and explore how the monoclonal antibody spesolimab is being investigated to prevent severe, unpredictable flares.

© 2024 MJH Life Sciences

All rights reserved.